ICH guidelines are a set of internationally agreed-upon standards that govern how new medicines are developed, tested, and approved. They are created by the International Council for Harmonisation (ICH), an organization that brings together drug regulatory agencies and pharmaceutical industry representatives from around the world to align their requirements. The core goal: make drug development more efficient across borders while protecting public health, reducing duplicate clinical trials in humans, and minimizing animal testing. ICH currently has 25 member organizations, 41 observers, and a network of nearly 700 experts globally.
Who Created ICH and Why
ICH was founded as a partnership between three major regulatory agencies and their corresponding pharmaceutical industry associations. The regulatory side included the European Commission (EC), the U.S. Food and Drug Administration (FDA), and Japan’s Ministry of Health, Labour and Welfare alongside the Pharmaceuticals and Medical Devices Agency (MHLW/PMDA). The industry side included the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the Japan Pharmaceutical Manufacturers Association (JPMA).
Before ICH existed, a drug company seeking approval in the U.S., Europe, and Japan often had to run separate sets of studies to satisfy each region’s different requirements. This meant redundant clinical trials, wasted resources, and longer waits for patients who needed new treatments. ICH guidelines created a common playbook so that data generated in one region could be accepted in others.
The Four Guideline Categories
ICH organizes its guidelines into four broad categories, each designated by a letter.
Quality (Q)
Quality guidelines cover how a drug is manufactured and what standards it must meet. These include rules for stability testing (how long a drug remains effective under different storage conditions), acceptable levels of impurities, and a risk-based approach to pharmaceutical quality built on Good Manufacturing Practice. For example, the stability testing guideline Q1A(R2) specifies that drugs stored at room temperature must be tested under long-term conditions of 25°C and 60% relative humidity, as well as accelerated “stress” conditions of 40°C and 75% relative humidity, to predict shelf life. Refrigerated products are tested at 5°C for long-term storage and 25°C for accelerated studies. These standardized conditions mean a stability study run in one country produces data that regulators everywhere can evaluate on equal terms.
Safety (S)
Safety guidelines define the non-clinical (animal and laboratory) studies needed to identify potential risks before a drug is given to humans. These cover areas like cancer risk, genetic damage, and effects on reproduction. One notable achievement was establishing a standardized strategy for testing whether a drug can cause dangerous heart rhythm changes, which has been one of the most common reasons drugs get pulled from the market.
Efficacy (E)
Efficacy guidelines address how clinical trials in humans should be designed, conducted, and reported. This category also covers safety monitoring during trials and provides frameworks for newer types of medicines, including those made through biotechnology. The most widely known guideline in this category is E6, the Good Clinical Practice (GCP) standard, which sets the ethical and scientific quality requirements for any clinical trial involving human participants.
Multidisciplinary (M)
Multidisciplinary guidelines handle topics that cut across the other three categories. The most practically significant is the Common Technical Document (CTD), which standardizes the format drug companies use when submitting applications to regulatory agencies worldwide. This category also includes MedDRA, the standardized medical terminology system used for reporting adverse events, and electronic standards for transferring regulatory information.
Good Clinical Practice: The Most Referenced Guideline
ICH E6, the Good Clinical Practice guideline, is the single most frequently cited ICH standard. It establishes the ground rules for conducting clinical trials: informed consent, data integrity, investigator responsibilities, and protections for trial participants. Virtually every clinical trial conducted globally follows GCP principles.
The most recent revision, E6(R3), was finalized in September 2025. It represents a significant modernization. The updated guideline introduces flexible, risk-based approaches that accommodate modern trial designs, new data sources, and evolving technology. It also advances a concept called “quality by design,” which means building quality into the trial from the start rather than relying solely on inspection afterward. Sponsor and investigator responsibilities are more clearly defined, and the overall framework encourages proportionality, meaning the level of oversight should match the level of risk in a given trial.
The Common Technical Document
Before ICH created the Common Technical Document (CTD), every country had its own format for drug approval applications. The CTD standardized this into five modules that companies use everywhere they file.
- Module 1: Administrative information and prescribing details specific to each region, such as application forms and proposed labeling. This is the only region-specific module.
- Module 2: Summaries and overviews. This includes a general introduction to the drug (its class, how it works, proposed use) plus condensed versions of all the quality, non-clinical, and clinical data.
- Module 3: Detailed quality data covering how the drug is manufactured, its chemical and pharmaceutical properties, and specifications for biological or biotechnological products.
- Module 4: Full non-clinical study reports from animal and laboratory testing.
- Module 5: Full clinical study reports from human trials.
Modules 2 through 5 are identical regardless of where the application is submitted. This means a company preparing a filing for the FDA can use the same core dossier when applying to European or Japanese regulators, saving enormous amounts of time and duplication.
How a Guideline Gets Developed
ICH guidelines go through a formal five-step process that typically takes several years from start to finish.
It begins when the ICH Assembly endorses a concept paper and business plan for a new topic. An Expert Working Group is formed, drawing specialists from regulatory agencies and industry. In Step 1, this group builds consensus on a technical document. Once they agree, the document moves to Step 2, where the Assembly confirms sufficient scientific consensus exists and regulatory members formally adopt the draft guideline.
Step 3 is the most extensive phase. The draft leaves ICH and goes through public consultation in each region. Regulators, industry, academics, and patient groups can submit comments. The Expert Working Group then reviews all feedback, revises the document, and works toward a final consensus draft. At Step 4, the Assembly formally adopts the finished guideline as an ICH Harmonised Guideline. Step 5 is implementation, where each regulatory member incorporates the guideline into their own legal and regulatory framework.
How Guidelines Become Law in Each Region
An ICH guideline itself is not automatically binding. Each regulatory authority implements it according to its own national or regional rules. For example, the guideline on population exposure for long-term drugs (E1) was implemented in Europe in November 1994, by the FDA in March 1995, and in Japan in May 1995. Newer ICH members implement guidelines on their own timelines. China’s drug regulatory agency implemented that same E1 guideline in November 2022.
All ICH regulatory members are expected to implement all ICH guidelines. For regulatory observers (agencies that participate but aren’t yet full members), implementing certain guidelines is actually a prerequisite for gaining full membership. ICH conducts independent surveys to monitor how well guidelines are being adopted and followed across regions.
MedDRA: A Shared Medical Language
One of ICH’s more practical creations is MedDRA (the Medical Dictionary for Regulatory Activities), a standardized terminology system used to classify adverse events and other medical information in regulatory reporting. It uses a five-level hierarchy, moving from very specific to very general.
At the bottom are over 80,000 “Lowest Level Terms” that mirror how events are actually reported in practice, such as a patient’s own description of a symptom. These feed into “Preferred Terms,” each representing a single, distinct medical concept. Preferred Terms group into “High Level Terms” based on shared anatomy or function, which then roll up into “High Level Group Terms,” and finally into broad “System Organ Classes” organized by things like body system (gastrointestinal disorders) or cause (infections). This hierarchy allows regulators across the world to analyze safety data using consistent, comparable language, which is essential for detecting patterns that might signal a drug safety issue.